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IntroductIon
Development of ischemic ulcers, due to the underly-
ing occlusive vasculopathy, is a major clinical mani-
festation of systemic sclerosis (SSc) occurring in 35% 
to 60% of patients1. They tend to appear in the digits 
but also larger vessels of the lower extremities can 
be affected2. Scleroderma ulcers are associated with 
pain, reduced quality of life, disability, risk of infec-
tion, gangrene and amputation. Their management is 
often difficult. Therapeutic strategies include mainly 
vessel-wall acting agents. The dual endothelin-1 re-
ceptor antagonist bosentan was shown ineffective in 
ulcer healing1. Intravenous iloprost is effective but not 
all patients respond as well and its effect on prevention 
has not been studied3. Phosphodiesterase inhibitors are 
currently lacking sufficient data on ulcer healing.
In this context, hyperbaric oxygen therapy (HBOT) 
has been used successfully to treat chronic ulcers of 
vascular etiology. These ulcers are characterized by 
tissue hypoxia and HBOT has been demonstrated to 
increase oxygenation of hypoxic wound tissues and 
promote an anti-inflammatory effect thus stimulating 
angiogenesis and wound healing4.
We discuss a case of intractable ulcers in a patient 
with SSc, successfully treated with HBOT.
case report
A 75 year old Caucasian woman presented with sclero-
dactyly and Raynaud’s phenomenon in 1962 and was 
subsequently diagnosed with limited cutaneous SSc. 
Serologically, antinuclear antibodies were found to be 
positive at a titer of 1/1280 and she was also positive 
for antitopoisomerase I antibodies. Later in the course 
of the disease, contractures of the joints of the hands 
developed as well as pulmonary fibrosis, diastolic dys-
function of the heart and dilatation of esophagus. The 
patient had recurrent ulceration of the dorsal surface 
of the fingers of the hands, which were initially treated 
conservatively with dressings and administration of 
bosentan. In December 2009, the patient developed a 
painful ulcer at the left ankle (Figure 1). At that time, 
sildenafil was added instead of bosentan; still, three 
months later the ulcer worsen and in addition a second 
ulcer appeared at the first toe of the right foot (Figure 2).
Six months after the appearance of the ulcer at the 
left ankle a progressive deterioration of both ulcers 
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was apparent despite the performed therapy and the 
patient was referred by the vascular surgeon to the Hy-
perbaric Medicine Department.
In order to predict patient’s response to HBOT, 
Doppler, ankle / brachial pressure index and transcuta-
neous oximetry (TcPo2) were used (the patient had not 
underwent digital angiography). 
TcPo2 is measured in normobaric versus hyperbaric 
hyperoxia conditions and is considered to be the gold 
standard in the estimation of the diffusion of oxygen in 
the tissues during hyperbaric tissue hyperoxia (TcPo2 
> 300 mmHg) being reliable both in the selection of 
patients suitable for treatment as well as in the pre-
diction of the response to treatment. In this particular 
case, though the TcPo2 at the left foot under normo-
baric hyperoxic conditions was not in favor, it pre-
sented remarkable results under hyperbaric hyperoxia. 
Specifically the TcPo2 at the left foot under hyperoxic 
conditions was over 350 mmHg and at the right foot 
over 770 mmHg.
A series of 34 HBO sessions at 244 kPa (2.4 ATA) 
for 90 minutes was performed plus daily ulcers de-
bridement in order to remove necrotic tissues–exu-
dates and to provoke tissue granulation. 
One month after the end of the treatment protocol 
the patient showed complete healing of the ankle ul-
cer and a remarkable improvement in the ulcer of the 
toe. It should be noted that the patient did not need 
any more to undergo amputation of the toe, according 
to the vascular surgeon’s plan in the beginning. At 6 
months follow up healing remained intact (Figures 3, 
4). There were no complications associated with the 
HBO treatment.
dIscussIon
Digital ulcers develop in up to 35-60% of patients with 
scleroderma;1 they are intensely painful, slow to heal 
(3-15 months), and affect the quality of life significant-
ly. Their treatment remains suboptimal with amputa-
tion being an unavoidable final event in many cases. 
Thus treatment modalities that could facilitate healing 
of these ulcers are of great interest.
HBOT consists of inhalation of 100% (FiO2 1) 
oxygen when ambient pressure is higher than the at-
mospheric one. Oxygen gradient and thus diffusion 
in plasma is highly elevated and may restore im-
paired healing and immune response in different dis-
eases5. HBO therapeutic effect is well recognized so 
far through experimental and controlled clinical trials 
in different kind of ulcers. However evidence for its 
potential efficacy in SSc ulcers is sparse6. HBO pro-
motes the angiogenesis response of the lesion, a func-
tion known to be severely disturbed in SSc, through 
enhancement of fibroblasts proliferation, collagen 
maturation and bone marrow-derived endothelial pre-
cursor cells (EPCs) recruitment (de novo vessels for-
mation)7,8.
Although hypoxia is the main stimulator of 
wound healing, impaired microcirculation and tissue 
PO2 < 20 mmHg may lead to inappropriate repair-
Figure 1. The painful ulcer at the left ankle of the patient. Figure 2. The ulcer at the first toe of the right foot of the 
patient.
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ing mechanisms. Vascular endothelium growth factor 
(VEGF) has been identified as the primary growth fac-
tor implicated in neovascularisation. HBOT enhanc-
es the VEGF receptors response on endothelial cells 
(while hypoxia up-regulates them) promoting angio-
genesis and vasculogenesis9.
Furthermore impaired basal NO production may 
contribute greatly to the development of SSc vascular 
lesions by enhancing vasospasm, platelet aggregation 
and the up-regulation of endothelial and leucocyte ad-
hesion molecules (selectins, β integrins and intercel-
lular cell adhesion molecule/ ICAM1 1)10.
HBOT has being shown experimentally and clini-
cally to promote the NO synthesis and to down regulate 
the appearance of pro-inflammatory cytokines. HBOT 
exhibits its anti–inflammatory effect by stimulating 
phagocytosis of leucocytes and also by inhibiting spe-
cific cytokines of monocyte-macrophages as are IL-1, 
IL-6, IL-8 and TNF-a7,11. These cytokines have been 
shown to be upregulated in SSc12.
In this context, HBOT seems to interfere with criti-
cal pathways in the development of ulcers in SSc and 
may have a potential role in their healing. We provide 
evidence of healing of intractable ulcers in a patient 
with SSc with HBOT. This treatment modality may 
be proved a valuable supplement in the treatment al-
gorithm of SSc ulcers. Still, although this case report 
shows the beneficial effect of HBO, further research is 
needed to support its therapeutic action in SSc. Given 
the fact that HBO mechanisms of action target the 
pathophysiology of SSc ulcers a controlled random-
ized study could yield the above therapeutic effect as 
an adjunctive treatment in the therapeutic armamen-
tarium of these patients.
Figure 3. Complete healing of the ulcer at the left ankle of 
the patient.
Figure 4. Great improvement of the ulcer at the first toe of 
the right foot of the patient.
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ΠΕΡΙΛΗΨΗ: Η ανάπτυξη ισχαιμικών ελκών αποτελεί μείζονα κλινική εκδήλωση της συστηματικής σκλήρυνσης (ΣΣ). 
Η αντιμετώπιση των ελκών αυτών είναι συχνά δύσκολη παρά την ποικιλία θεραπευτικών μεθόδων που χρησιμοποιούνται. 
Αυτή η εργασία παρουσιάζει ένα περιστατικό δυσίατων ελκών σε μία ασθενή με ΣΣ, τα οποία αντιμετωπίστηκαν επιτυχώς 
με θεραπεία με Υπερβαρικό Οξυγόνο.
Λέξεις Κλειδιά: Χρόνια έλκη, Υπερβαρικό οξυγόνο.
Θεραπεία με υπερβαρικό οξυγόνο δυσίατων ελκών σε ασθενή  
με συστηματική σκλήρυνση: Περιγραφή περιστατικού.
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